4D Molecular Therapeutics Inc. (FDMT) Social Stream
4D MOLECULAR THERAPEUTICS INC (FDMT) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering 4D MOLECULAR THERAPEUTICS INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-12-10 | 3 | $70 | $45 | $57.5 | $19.22 | 199.17% |
| 2022-01-04 | 2 | $45 | $30 | $37.5 | $19.22 | 95.11% |
| 2022-03-29 | 2 | $42 | $30 | $36 | $19.22 | 87.3% |
| 2022-04-04 | 2 | $37 | $30 | $33.5 | $19.22 | 74.3% |
| 2022-05-12 | 2 | $37 | $28 | $32.5 | $19.22 | 69.09% |
| 2022-05-27 | 3 | $28 | $15 | $21.5 | $19.22 | 11.86% |
| 2022-06-22 | 3 | $28 | $15 | $21.666 | $19.22 | 12.73% |
| 2022-08-13 | 3 | $28 | $15 | $21.666 | $19.22 | 12.73% |
| 2022-09-17 | 3 | $22 | $12 | $16.333 | $19.22 | -15.02% |
| 2022-10-27 | 3 | $22 | $10 | $15.666 | $19.22 | -18.49% |
| 2022-11-11 | 3 | $22 | $11 | $16 | $19.22 | -16.75% |
| 2022-11-14 | 4 | $45 | $11 | $23.25 | $19.22 | 20.97% |
| 2022-11-15 | 5 | $68.001 | $15 | $35 | $19.22 | 82.1% |
| 2022-11-21 | 5 | $68.001 | $15 | $35.166 | $19.22 | 82.97% |
| 2023-01-25 | 5 | $68.001 | $15 | $36 | $19.22 | 87.3% |
| 2023-02-03 | 6 | $68.001 | $15 | $38 | $19.22 | 97.71% |
| 2023-02-08 | 6 | $68.001 | $14 | $37.571 | $19.22 | 95.48% |
| 2023-03-27 | 6 | $68.001 | $14 | $37.857 | $19.22 | 96.97% |
| 2023-04-27 | 6 | $68.001 | $13 | $37.714 | $19.22 | 96.22% |
| 2023-05-05 | 6 | $68.001 | $22 | $39 | $19.22 | 102.91% |
| 2023-05-11 | 6 | $68.001 | $21 | $38.857 | $19.22 | 102.17% |
| 2023-06-06 | 6 | $68.001 | $23 | $39.143 | $19.22 | 103.66% |
The Trend in the Analyst Price Target
FDMT's average price target has moved down $4.86 over the prior 29 months.
FDMT reports an average of 97.91% for its upside potential over the past 50 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-09-17 | 3 | 22.000 | 12 | 16.333 | 8.85 | 84.55% |
| 2022-11-15 | 4 | 68.001 | 15 | 35.000 | 18.69 | 87.27% |
| 2023-01-25 | 5 | 68.001 | 15 | 36.000 | 20.43 | 76.21% |
| 2023-02-08 | 6 | 68.001 | 14 | 37.571 | 20.54 | 82.92% |
| 2023-04-27 | 6 | 68.001 | 22 | 39.000 | 16.50 | 136.36% |
FDMT Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.33 | 5 | 0 | 1 | 0 | 0 | 6 |
The Trend in the Broker Recommendations
Over the past 20 months, FDMT's average broker recommendation rating worsened by 0.33.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for FDMT as an investment opportunity.
- FDMT has a higher number of analysts covering the stock than 422.45% of all US stocks.
- To contextualize these metrics, consider that out of all US stocks, 4D MOLECULAR THERAPEUTICS INC's variance in analysts' estimates is lower than -1837.7% of them.
- In terms of how 4D MOLECULAR THERAPEUTICS INC fares relative to stocks in the small market cap category, note that its average analyst price target is greater than 1933.53% of that group.
- FDMT has a greater upside potential (average analyst target price relative to current price) than 885.01% of Pharmaceutical Products stocks.
Stocks similar to 4D MOLECULAR THERAPEUTICS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are CGEM, GRNA, and FNCH.
View All Top Stocks by Price Target
What is the outlook for FDMT? Use POWR Ratings for clearer insight into price direction.